87.26USD-0.83%Mkt Cap: —P/E: —1d ago
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasir…
Industry Peers
Biotechnology$139.84BUSDP/E 32.2
$85.11BUSDP/E 20.4
$69.62BUSD
$60.19BUSDP/E 39.1
$45.16BUSDP/E 19.2
$46.01BUSD
$41.76BUSDP/E 66.2
$35.67BUSDP/E 33.2
$32.46BUSDP/E 42.3
$28.53BUSD
$26.14BUSD
$25.79BUSDP/E 16.2
$20.83BUSDP/E 26.3
$19.17BUSDP/E 26.2
$17.03BUSDP/E 20.0
$16.41BUSD
$13.48BUSDP/E 17.1
$13.42BUSDP/E 187.4
$12.87BUSDP/E 264.5
$12.59BUSD
Key Statistics
Company
Market Cap—
Enterprise Value11.97B $
Revenue (TTM)669.49M $
Gross Profit669.49M $
Net Income (TTM)-319.96M $
Revenue/Share4.766 USD
Last Price87.26 USD
Fiscal Year EndSep 2025
MR QuarterJun 2026
Employees711
CountryGB
SectorHealthcare
IndustryBiotechnology
ISINUS04280A1007
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-59.66
EV/Revenue17.88
P/S—
P/B26.25
EPS (TTM)-1.07
EPS (Forward)—
52W Range
86.2124% of range90.50
52W High90.50 USD
52W Low86.21 USD
Profitability
Gross Margin100.00%
Oper. Margin-226.03%
EBITDA Margin-29.97%
Profit Margin-47.79%
ROE-55.21%
ROA-8.10%
Growth
Revenue Growth171.00%
Earnings Growth—
Cash Flow & Leverage
Operating CF-59.05M $
CapEx (TTM)—
FCF Margin-7.26%
FCF Yield—
Net Debt-218.45M $
Net Debt/EBITDA1.09
Balance Sheet
Debt/Equity295.98
Current Ratio5.90
Quick Ratio5.71
Book Value/Sh3.298 USD
Cash/Share11.31 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.88.02M
Float122.45M
Insiders3.67%
Institutions85.57%
Technical
SMA 5032.83 (+165.8%)
SMA 20031.06 (+181.0%)
Beta1.29
S&P 52W Chg20.80%
Avg Vol (30d)525
Avg Vol (10d)1.82K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—